HMGB1 release in colon carcinoma cells is mainly responsible for 5‐FU elicited leucocyte attraction and defined as a novel limiting target for combinatorial therapies, which could be prevented by HMGB1‐blocking antibodies or A box protein 131. The gene discussed is HMGB1; the disease is colon carcinoma.